Key facts
- It has raised $96.6M; the latest was Later Stage VC ($49.4M) in May 2024.
- Notable investors include Kinled Holding, Verve Ventures, Zürcher Kantonalbank, Redalpine, Kurma Partners — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Memo Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Memo Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Memo Therapeutics
Developer of antibody discovery and immune repertoire analysis platform designed to transform the lives of patients with virus infections and cancer. The company's platform creates a recombinant in vitro copy of an individual's B cell/antibody repertoire that leads to entirely new possibilities in immune repertoire analysis and antibody discovery, enabling physicians to progress molecular cloning, biobanking, and expression-screening of all the antibodies in an organism.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Founded
- 2012
- Employees
- 44
- Website
- memo-therapeutics.com/
- Ownership
- Privately Held (backing)
Memo Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Memo Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Memo Therapeutics in its N-PORT filings yet. We sweep new filings monthly.